Taconic Biosciences, a global leader in providing animal model solutions and services, has entered into an exclusive license agreement with Helmholtz Munich, one of Germany's leading biomedical research centers, to provide preclinical researchers with advanced CRISPR gene editing services. The partnership grants Taconic exclusive rights to a patented CRISPR-based gene editing technology developed at Helmholtz Munich to improve the generation of genetically modified animal models for biomedical research.
Enhanced Platform Capabilities
The new technology significantly enhances Taconic's ExpressMODEL® platform to deliver high-quality, precise CRISPR/Cas9-generated custom animal models on an accelerated timeline to customers. "Taconic is excited to expand our already extensive capabilities in CRISPR/Cas9 gene editing through this new partnership with Helmholtz Munich," said Mike Garrett, Chief Executive Officer of Taconic Biosciences. "This technology significantly enhances Taconic's ExpressMODEL® platform to deliver high-quality, precise CRISPR/Cas9-generated custom animal models on an accelerated timeline to our customers."
Strategic Partnership for Scientific Discovery
The collaboration combines Helmholtz Munich's innovative CRISPR technology with Taconic's expertise in animal model generation and breeding. Prof. Dr. Wolfgang Wurst, co-inventor of the licensed technology at Helmholtz Munich, explained the partnership's scientific objectives: "This agreement with Taconic will deepen our understanding of gene function by enabling the development of advanced, genetically engineered animal models. By combining our innovative CRISPR technology with Taconic's expertise in animal model generation and breeding, we aim to accelerate the creation of precise models that uncover the genetic basis of diseases — supporting scientific discovery and paving the way for future medical breakthroughs."
Industry Leadership in Gene Editing
Taconic has been a pioneer in CRISPR/Cas9 gene editing services for over a decade and remains at the forefront of advanced gene-modification methodologies. By exclusively licensing Helmholtz Munich's groundbreaking gene editing techniques and applications, Taconic Biosciences strengthens its position as a leader in the commercialization of cutting-edge CRISPR gene editing services.
The partnership marks a significant milestone in Taconic's commitment to providing researchers with advanced tools for biomedical research. By integrating novel CRISPR/Cas9 technologies with proven expertise in model generation, the collaboration supports the rapid development of scientific breakthroughs and improved translation of genetic research into therapeutic innovation.
